公开(公告)号：US20200039965A1

公开(公告)日：2020-02-06

申请号：US16339056

申请日：2017-10-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Matthew D. Cheeseman ,  A. Elisa Pasqua ,  Michael J. Tucker

IPC: C07D405/12

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.

公开(公告)号：US11814370B2

公开(公告)日：2023-11-14

申请号：US16339056

申请日：2017-10-06

Applicant: Cancer Research Technology Limited

Inventor： Keith Jones ,  Matthew D. Cheeseman ,  A. Elisa Pasqua ,  Michael J. Tucker

IPC: C07D405/12 ,  C07B59/00 ,  A61P35/00

CPC classification number: C07D405/12 ,  C07B59/002 ,  A61P35/00 ,  C07B2200/05

Abstract: The present invention relates to N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one hydrogen atom has been substituted with a deuterium atom. Other aspects include pharmaceutical compositions comprising said compounds and medical uses and methods of treatment using said compounds.